A multiple sclerosis disease progression measure based on cumulative disability

被引:2
|
作者
Manouchehrinia, Ali [1 ]
Kingwell, Elaine [2 ,3 ]
Zhu, Feng [2 ,3 ]
Tremlett, Helen [2 ,3 ]
Hillert, Jan [1 ]
Ramanujam, Ryan [1 ,4 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Clin Neurosci, Stockholm, Sweden
[2] Univ British Columbia, UBC Hosp, Fac Med Neurol, Vancouver, BC, Canada
[3] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada
[4] Royal Inst Technol, Dept Math, Stockholm, Sweden
基金
加拿大健康研究院;
关键词
Multiple sclerosis; progression measure; outcome; disability;
D O I
10.1177/1352458520988632
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. Objective: The objective of this study is to create a severity metric that can reliably summarize a patient's disease course. Methods: We developed the nARMSS - normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from -5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. Results: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. Conclusion: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible.
引用
收藏
页码:1875 / 1883
页数:9
相关论文
共 50 条
  • [41] Plasma lipid peroxidation and progression of disability in multiple sclerosis
    Koch, M.
    Mostert, J.
    Arutjunyan, A. V.
    Stepanov, M.
    Teelken, A.
    Heersema, D.
    De Keyser, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (05) : 529 - 533
  • [42] Psychiatric comorbidity is associated with disability progression in multiple sclerosis
    McKay, Kyla A.
    Tremlett, Helen
    Fisk, John D.
    Zhang, Tingting
    Patten, Scott B.
    Kastrukoff, Lorne
    Campbell, Trudy
    Marrie, Ruth Ann
    NEUROLOGY, 2018, 90 (15) : E1316 - E1323
  • [43] Serum NSE level and disability progression in multiple sclerosis
    Koch, Marcus W.
    George, Suzanne
    Wall, Winona
    Yong, V. Wee
    Metz, Luanne M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 350 (1-2) : 46 - 50
  • [44] Effect of smoking on disability progression in patients with multiple sclerosis
    Gunduz, Tuncay
    Kurtuncu, Murat
    TOBACCO INDUCED DISEASES, 2018, 16 : 28 - 28
  • [45] Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability
    Ana Paula Kallaur
    Sayonara Rangel Oliveira
    Andréa Name Colado Simão
    Daniela Frizon Alfieri
    Tamires Flauzino
    Josiane Lopes
    Wildea Lice de Carvalho Jennings Pereira
    Caio de Meleck Proença
    Sueli Donizete Borelli
    Damacio Ramón Kaimen-Maciel
    Michael Maes
    Edna Maria Vissoci Reiche
    Molecular Neurobiology, 2017, 54 : 2950 - 2960
  • [46] Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
    Amato, Maria Pia
    Fonderico, Mattia
    Portaccio, Emilio
    Pasto, Luisa
    Razzolini, Lorenzo
    Prestipino, Elio
    Bellinvia, Angelo
    Tudisco, Laura
    Fratangelo, Roberto
    Comi, Giancarlo
    Patti, Francesco
    De Luca, Giovanna
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Pozzilli, Carlo
    Sola, Patrizia
    Bergamaschi, Roberto
    Salemi, Giuseppe
    Inglese, Matilde
    Millefiorini, Enrico
    Galgani, Simonetta
    Zaffaroni, Mauro
    Ghezzi, Angelo
    Salvetti, Marco
    Lus, Giacomo
    Florio, Ciro
    Totaro, Rocco
    Granella, Franco
    Vianello, Marika
    Gatto, Maurizia
    Di Battista, Giancarlo
    Aguglia, Umberto
    Logullo, Francesco Ottavio
    Simone, Marta
    Lucisano, Giuseppe
    Iaffaldano, Pietro
    Trojano, Maria
    BRAIN, 2020, 143 : 3013 - 3024
  • [47] Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability
    Kallaur, Ana Paula
    Oliveira, Sayonara Rangel
    Colado Simao, Andrea Name
    Alfieri, Daniela Frizon
    Flauzino, Tamires
    Lopes, Josiane
    de Carvalho Jennings Pereira, Wildea Lice
    Proenca, Caio de Meleck
    Borelli, Sueli Donizete
    Kaimen-Maciel, Damacio Ramon
    Maes, Michael
    Vissoci Reiche, Edna Maria
    MOLECULAR NEUROBIOLOGY, 2017, 54 (04) : 2950 - 2960
  • [48] A novel retinal phenotype in multiple sclerosis is predictive of inflammatory disease activity and disability progression
    Saidha, S.
    Sotirchos, E.
    Ibrahim, M.
    Gelfand, J.
    Sepah, Y.
    Ratchford, J.
    Oh, J.
    Seigo, M.
    Newsome, S.
    Balcer, L.
    Frohman, E.
    Crainiceanu, C.
    Green, A.
    Nguyen, Q.
    Calabresi, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 10 - 11
  • [49] Impact of insulin resistance and metabolic syndrome on disability and disease progression in patients with multiple sclerosis
    Soliman, R. H.
    Hassan, A.
    Farhan, H. M.
    Hegazy, M.
    Oraby, M. I.
    Kamel, S. H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 487 - 487
  • [50] ARE NEUROPHYSIOLOGICAL PARAMETERS AN OBJECTIVE MEASURE OF DISEASE STATUS AND PROGRESSION IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS?
    Witherick, J.
    Kane, N.
    Butler, S.
    Walsh, P.
    Blake, K.
    Faulkner, H.
    Burrows, J.
    Inglis, K.
    Cottrell, D.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2012, 83 (03):